- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02142335
Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma
A Phase II Trial of the Combination of Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
Rituxan and Abraxane are approved for the treatment of other cancers, but not for melanoma. Candidates for this study have melanoma that has spread to their lymph nodes or internal organs and that cannot be removed by a surgical procedure.
The safety of this combination of drugs will also be looked at throughout this study.
Rituxan will be administered IV at weeks 1 and 3 of each cycle. Abraxane will be administered IV weekly for 3 consecutive weeks. This is followed by 1 week of rest after which, the cycle is repeated. Following the second cycle, there will be a 4-week period of rest. Evaluation of response will occur on day 71 +/-3 days. If either disease stabilization or clear evidence of clinical response is observed two additional cycles of treatment will be administered. Lesions will be measured on the scan (CT or PET/CT), x-ray
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Edward F McClay, MD
- Telefonnummer: 760-452-3340
- E-post: emcclay@pacificoncology.com
Studera Kontakt Backup
- Namn: Beth Kimball, OCN, RN
- Telefonnummer: 760-452-3909
- E-post: bkmball@pacificoncology.com
Studieorter
-
-
California
-
Encinitas, California, Förenta staterna, 92024
- Rekrytering
- California Cancer Associates For Research,cCARE
-
Kontakt:
- Edward F McClay, M.D.
- Telefonnummer: 760-452-3340
- E-post: emcclay@pacificoncology.com
-
Kontakt:
- Beth c Kimball, RN, OCN
- Telefonnummer: 760-452-3909
- E-post: bkimball@pacificoncology.com
-
Huvudutredare:
- Edward F. McClay, M.D.
-
Underutredare:
- Alberto Bessudo, M.D.
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Patients must have inoperable stage III and IV melanoma.
Patients will be included in the trial based on the following criteria:
Patients previously treated with no more than 1 non-abraxane containing chemotherapy regimen or patients with the B-Raf mutation, who have received vemurafenib or the combination of Dabrafinib and trametinib (or similar compound on clinical trial) and progressed, who have documented surgically inoperable stage III or IV metastatic melanoma on pathologic examination of tissue. Previous treatment with immunotherapy is allowed. Patients who have been treated with either immunotherapy or chemotherapy must have be either 4 weeks from their last treatment or have fully recovered from all previous treatment.
Measurable or evaluable non-CNS disease required as defined:
- Uni-dimensionally measurable lesion as determined by physical exam, X-ray, CT scan, MRI, or other radiographic procedure.
- Lesion that can be seen on a radiologic test but is not uni-dimensionally measurable
- Previously irradiated lesion allowed only with documentation of progression if no other metastatic site present.
No active brain metastases Patients with previously treated brain metastases that have responded to therapy will be allowed on study assuming there is measurable disease outside of the CNS. Active therapy for the CNS disease must be completed a minimum of 3 weeks for chemotherapy and 6 weeks for radiation therapy (prior to enrollment on this study).
Prior/ Concurrent therapy
Biologic therapy No concurrent biological therapy with the exception of growth factors for anemia, neutropenia or thrombocytopenia.
Chemotherapy No greater than 1 previous non-abraxane containing chemotherapy treatment allowed
Radiotherapy At least 6 weeks since completion of radiotherapy
Patient characteristics Age and ability to give informed consent Patients must be 18 years of age or older. Patients must have the ability to give informed consent.
Performance status ECOG 0-2 Life expectancy of at least 3 months
General Medical Concerns:
- Normal organ function, except if abnormal due to tumor involvement.
- Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months after completion of treatment.
- Subject has provided written informed consent.
Rituximab-Specific Concerns:
- ANC: > 1200/mm3
- Platelets: > 100,000/mm3
- Hemoglobin: > 9 gm/dL
- Adequate renal function as indicated by serum creatinine measurement < 1.5 x the upper limit of normal or GFR > 50 ml/min.
- Adequate liver function, as indicated by bilirubin < 3.0
- AST or ALT <2x Upper Limit of Normal unless related to primary disease.
- AST or ALT <5x Upper limit of Normal if evidence of liver metastasis.
Exclusion Criteria:
- Life expectancy less than 3 months
Untreated brain metastasis
Previous treatment with Abraxane containing regimen
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Rituxan/Abraxane
This is a single arm study.
All patients recieve treatment.
|
The dose of Rituxan is 375 mg/m2¬ administered as an IV infusion during weeks 1 & 3 (days 1 & 15)Abraxane will be administered at a fixed dose of 100 mg/m2 as an IV infusion weekly for three weeks in a row followed by one week of rest
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Overall response as determined by a Percent change (%) in the sum of the diameters of target lesions.
Tidsram: baseline-12 weeks
|
Evaluation of response (Progression Free and overall survival will be determined by measuring and recording the largest diameter of a lesion. Add these values together and record the value as the sum of the largest diameters.The percent change will be obtained according to the following formula: Percent change = sum of the longest diameter at 12weeks X 100 Sum of the longest diameters pre treatment |
baseline-12 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Response rate as Percent change in diameter (mm) of target lesions
Tidsram: 2 years
|
Overall response rate ( complete response + Partial response) will be determined by the disappearance of lesions or a reduction of target lesions in short axis to <10mm (CR) + at least a 30% decrease in the sum of the longest diameters of the target lesions (PR).
|
2 years
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Edward F. McClay, M.D., California Cancer Assocaties for Research & Excellence
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter histologisk typ
- Neoplasmer
- Neuroektodermala tumörer
- Neoplasmer, könsceller och embryonala
- Neoplasmer, nervvävnad
- Neuroendokrina tumörer
- Nevi och melanom
- Melanom
- Läkemedels fysiologiska effekter
- Antireumatiska medel
- Antineoplastiska medel
- Immunologiska faktorer
- Antineoplastiska medel, immunologiska
- Rituximab
Andra studie-ID-nummer
- ML29065
- 20132169 (Annan identifierare: WIRB)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Metastaserande melanom
-
PfizerAvslutadBRAF eller NRAS Mutant Metastatic MelanomFörenta staterna, Nederländerna, Italien, Tyskland, Schweiz
-
I-Mab Biopharma Co. Ltd.Inte längre tillgängligSolid Tumor Metastatic Cancer Advanced Cancer
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RekryteringMetastaserande melanom | Konjunktivalt melanom | Okulärt melanom | Ooperabelt melanom | Uveal melanom | Kutant melanom | Slemhinnemelanom | Iris melanom | Akralt melanom | Icke-kutant melanomFörenta staterna
-
MelanomaPRO, RussiaRekryteringMelanom | Melanom (hud) | Melanom Steg IV | Melanom stadium III | Melanom, stadium II | Melanom, Uveal | Melanom in Situ | Melanom, OkulärRyska Federationen
-
National Cancer Institute (NCI)AvslutadÅterkommande melanom | Steg IIIA melanom | Steg IIIB melanom | Steg IIIC melanom | Steg IIB melanom | Steg IIC melanom | Steg IA melanom | Steg IB melanom | Steg IIA melanomFörenta staterna
-
University of Southern CaliforniaNational Cancer Institute (NCI)AvslutadÅterkommande melanom | Steg IV melanom | Slemhinnemelanom | Ciliary Body och Choroid Melanom, Medium/Large Storlek | Ciliarkropp och koroid melanom, liten storlek | Iris melanom | Metastaserande intraokulärt melanom | Återkommande intraokulärt melanom | Steg IV Intraokulärt melanom | Steg IIIA melanom | Steg... och andra villkorFörenta staterna
-
Mayo ClinicNational Cancer Institute (NCI)AvslutadÅterkommande melanom | Steg IV melanom | Steg IIIA melanom | Steg IIIB melanom | Steg IIIC melanom | Steg IIB melanom | Steg IIC melanom | Steg IIA melanomFörenta staterna
-
BiocadRekryteringMelanom | Melanom (hud) | Melanom Steg IV | Melanom stadium III | Melanom Metastaserande | Melanom ooperabelt | Melanom AvanceratIndien, Ryska Federationen, Belarus
-
National Cancer Institute (NCI)AvslutadSteg IV melanom | Ciliary Body och Choroid Melanom, Medium/Large Storlek | Iris melanom | Steg IIIA melanom | Steg IIIB melanom | Steg IIIC melanom | Extraokulärt förlängningsmelanom | Steg IIB melanom | Steg IIC melanomFörenta staterna
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkAvslutadÅterkommande melanom | Steg IV melanom | Metastaserande intraokulärt melanom | Återkommande intraokulärt melanom | Steg IV Intraokulärt melanom | Steg IIIA melanom | Steg IIIB melanom | Steg IIIC melanom | Extraokulärt förlängningsmelanom | Steg IIIA Intraokulärt melanom | Steg IIIB Intraokulärt melanom | Steg...Förenta staterna
Kliniska prövningar på Rituxan
-
University of VermontGenentech, Inc.AvslutadRefraktär Myasthenia GravisFörenta staterna
-
National Institute of Allergy and Infectious Diseases...Rho Federal Systems Division, Inc.; Clinical Trials in Organ Transplantation...Avslutad
-
Georgetown UniversityHackensack Meridian HealthAktiv, inte rekryterandeKronisk lymfatisk leukemiFörenta staterna
-
German Parkinson Study Group (GPS)Philipps University Marburg Medical Center; MSE Pharmazeutika GmbH, Louisenstr... och andra samarbetspartnersAvslutadProgressiv supranukleär paresTyskland
-
Hangzhou DAC Biotechnology Co., Ltd.Har inte rekryterat ännuAvancerade solida tumörer | Hematologiska maligniteter
-
Mclean HospitalNational Alliance for Research on Schizophrenia and DepressionAvslutad
-
Cooperative International Neuromuscular Research...AvslutadMuskeldystrofi, DuchenneFörenta staterna
-
Massachusetts General HospitalGenentech, Inc.IndragenNjurinsufficiens | Kronisk avstötning
-
Massachusetts General HospitalGenentech, Inc.; BiogenIndragen
-
Genentech, Inc.AvslutadMikroskopisk polyangit | Granulomatos med polyangiitFörenta staterna